Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA

European Respiratory Review

Volumn 24, Issue 136, 2015, Pages 340-355

  Wallerek, Sandra ^a   Sørensen, Jens Benn ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BAG 1 PROTEIN; BETA TUBULIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MUCIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; PROTEIN INTR; PROTEIN KINASE B; PROTEIN MSH2; PROTEIN P27; PROTEIN P53; PROTEIN RRM1; PROTEIN TS; PROTEIN TUBB3; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; TUMOR MARKER; UFT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; DISEASE FREE SURVIVAL; DNA MICROARRAY; DNA SYNTHESIS; DRUG EFFICACY; EXCISION REPAIR; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATORY CELL; LUNG CANCER; NEUTROPHIL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SQUAMOUS CELL LUNG CARCINOMA; TUMOR CELL; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; LUNG NEOPLASMS; LUNG RESECTION; METABOLISM; MORTALITY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84930452903     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00005814     Document Type: Review

References (74)

1. World Health Organization (WHO). Cancer. Fact sheet no. 297. www.who.int/mediacentre/factsheets/fs297/en/ Date last acccessed: November 28, 2013. Date last updated: February 2014.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.
3. Herbst RS, Heymach JV, Lippman SM et al. Lung cancer. N Engl J Med 2008; 359: 1367–1380.
4. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 2013; 11: 645–653.
5. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899–909.
6. Stewart LA, Burdett S, Tierney F, et al. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol 2007; 25: Suppl. 18, 7552.
7. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552–3559.
8. Crinò L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: Suppl. 5, v103–v115.
9. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) Edn of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706–714.
10. Detterbeck FC, Lewis SZ, Diekemper R, et al. Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: Suppl. 5, 7S–37S.
11. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180–1184.
12. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? Breast Cancer Res Treat 1998; 52: 305–319.
13. Ilie M, Hofman V, Ortholan C, et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 2012; 118: 1726–1737.
14. Sève P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res 2007; 13: 994–999.
15. Reiman T, Lai R, Veillard AS, et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials. Ann Oncol 2012; 23: 86–93.
16. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008; 62: 105–112.
17. Pesta M, Kulda V, Fiala O, et al. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res 2012; 32: 5003–5010.
18. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983–991.
19. Leng XF, Chen MW, Xian L, et al. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res 2012; 31: 25.
20. Cubukcu E, Fatih Olmez O, Saraydaroglu O, et al. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: Implications for patient outcome. Clin Transl Oncol 2011; 13: 826–830.
21. Pierceall WE, Olaussen KA, Rousseau V, et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 2012; 23: 2245–2252.
22. Graziano SL, Gu L, Wang X, et al. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: A laboratory companion study to CALGB 9633. J Thorac Oncol 2010; 5: 810–817.
23. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25: 5240–5247.
24. Filipits M, Haddad V, Schmid K, et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 2007; 13: 3892–3898.
25. Kamal NS, Soria JC, Mendiboure J, et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010; 16: 1206–1215.
26. Nakano J, Huang C, Liu D, et al. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006; 95: 607–615.
27. Miyoshi T, Kondo K, Toba H, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur +uracil) in patients with non-small cell lung cancer. Anticancer Res 2007; 27: 2641–2648.
28. Shi Y, Chen L, Li J, et al. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol 2011; 32: 381–390.
29. Voortman J, Goto A, Mendiboure J, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010; 70: 8288–8298.
30. Yan S, Shun-Chang J, Li C, et al. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer 2010; 10: 621.
31. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010; 28: 4417–4424.
32. Chen DT, Hsu YL, Fulp WJ, et al. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst 2011; 103: 1859–1870.
33. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: Development and international validation studies. Lancet 2012; 379: 823–832.
34. Wistuba II, Behrens C, Lombardi F, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 2013; 19: 6261–6271.
35. Levallet G, Bergot E, Antoine M, et al. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther 2012; 11: 1203–1213.
36. Stubbe J. Ribonucleotide reductases in the twenty-first century. Proc Natl Acad Sci USA 1998; 95: 2723–2724.
37. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800–808.
38. Altaha R, Liang X, Yu JJ, et al. Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int J Mol Med 2004; 14: 959–970.
39. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013; 368: 1101–1110.
40. Paterson JW. BRCA1: A review of structure and putative functions. Dis Markers 1998; 13: 261–274.
41. Wachters FM, Wong LS, Timens W, et al. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005; 50: 211–219.
42. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: A novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007; 2: e1129.
43. May P, May E. Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene 1999; 18: 7621–7636.
44. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006; 86: 849–899.
45. Zdraveski ZZ, Mello JA, Farinelli CK, et al. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem 2002; 277: 1255–1260.
46. Duckett DR, Drummond JT, Murchie AI, et al. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 1996; 93: 6443–6447.
47. Kaneda S, Nalbantoglu J, Takeishi K, et al. Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem 1990; 265: 20277–20284.
48. Krajewska M, Turner BC, Shabaik A, et al. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. Prostate 2006; 66: 801–810.
49. Liu H, Liang Y, Li Y, et al. Gene silencing of BAG-1 modulates apoptotic genes and sensitizes lung cancer cell lines to cisplatin-induced apoptosis. Cancer Biol Ther 2010; 9: 832–840.
50. Kellner U, Sehested M, Jensen PB, et al. Culprit and victim – DNA topoisomerase II. Lancet Oncol 2002; 3: 235–243.
51. Bepler G, Olaussen KA, Vataire AL, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 2011; 178: 69–78.
52. Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007; 25: 2735–2740.
53. Van Laar RK. Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer. BMC Med Genomics 2012; 5: 30.
54. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59–66.
55. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010; 67: 101–107.
56. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95: 1453–1461.
57. Douillard JY, Rosell R, De Lene M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006; 7: 719–727.
58. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713–1721.
59. Nakagawa K, Tada H, Akashi A, et al. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer 2006; 95: 817–821.
60. Bennouna J, Senellart H, Hiret S, et al. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: Subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer 2011; 74: 30–34.
61. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol 2010; 28: 29–34.
62. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043–5051.
63. McCarty KS Jr, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46: Suppl., 4244s–4248s.
64. Deepak S, Kottapalli K, Rakwal R, et al. Real-time PCR: Revolutionizing detection and expression analysis of genes. Curr Genomics 2007; 8: 234–251.
65. Petrosyan F, Daw H, Haddad A, et al. Gene expression profiling for early-stage NSCLC. Am J Clin Oncol 2015; 38: 103–107.
66. Vilmar A, Garcia-Foncillas J, Huarriz M, et al. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer 2012; 75: 306–312.
67. Bergot E, Levallet G, Campbell K, et al. Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev 2013; 22: 565–576.
68. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385–2394.
69. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239–246.
70. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–128.
71. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327–3334.
72. Shepherd FA, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial. J Clin Oncol 2014; 32: Suppl. 15, 7513.
73. Kelly K, Altorki NK, Eberhardt WE, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. J Clin Oncol 2014; 32: Suppl. 15, 7501.
74. Pennell NA, Neal JW, Chaft JE, et al. SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. J Clin Oncol 2014; 32: Suppl. 15, 7514.